Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5094 participants.
Also called NCT03252249
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,094 participants
- Registry
-
NCT03252249
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- New Zealand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03252249. Randomized; no masking; primary purpose treatment. Start 2018-04-26 (actual); primary completion 2023-02-04 (actual). Results posted on 2026-01-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
- Condition
- Acute Coronary Syndrome
- Condition
- Coronary Artery Disease
- Intervention (Other)
- 3 months dual anti-platelet therapy
- Intervention (Other)
- 12 months dual anti-platelet therapy
- Lead sponsor
- University of Edinburgh
- Collaborator
- British Heart Foundation
Record details
- Record id
cardio:ct-nct03252249- Content hash
41d15b96eb859c87a8c26f402e61af69cc93662d1147a847e83109ccafee4630